Capitainer AB, based in Stockholm, Sweden, specializes in the manufacture of a volumetric blood collection device designed for micro sampling with a predefined blood volume. Founded in 2016, the company provides patients with the ability to collect their own dried blood spots at home, ensuring convenience and safety. This innovative technology offers a more accurate solution compared to existing methods, while also delivering significant cost and environmental benefits for healthcare providers that handle large volumes of conventional blood samples.
PharmNovo AB is a Swedish biopharmaceutical company based in Lund, established in 2008. It specializes in the development of therapeutic drugs aimed at treating neuro diseases, particularly hyper excitability disorders such as chronic pain. The company's leading product, PN6047, is designed to alleviate chronic pain and address issues of hypersensitivity. PharmNovo employs a research approach that integrates advanced chemistry and bioscience to create safe, effective, and non-addictive opioid alternatives for managing nervous system disorders. By focusing on neuroscience and translational medicine, PharmNovo aims to enhance the quality of life for individuals suffering from chronic pain.
Encare AB, founded in 2009 and based in Stockholm, Sweden, specializes in web-based software solutions designed to enhance surgical care through the implementation of Enhanced Recovery after Surgery (ERAS) protocols. The company offers a comprehensive suite of tools, including an ERAS protocol for perioperative care, an audit system for surgeries, an implementation tool, and a system for comparing outcomes. Encare's interactive platform allows surgical teams to collect and analyze critical performance data, providing immediate feedback that fosters improvements in efficiency and quality of care. The software has been successfully deployed in over 120 hospitals across multiple countries, facilitating the training of healthcare professionals and promoting evidence-based best practices in perioperative management. Encare holds the rights to commercialize surgical protocols developed by the ERAS Society, which aims to establish standardized guidelines for enhanced recovery in surgical patients.
Capitainer AB, based in Stockholm, Sweden, specializes in the manufacture of a volumetric blood collection device designed for micro sampling with a predefined blood volume. Founded in 2016, the company provides patients with the ability to collect their own dried blood spots at home, ensuring convenience and safety. This innovative technology offers a more accurate solution compared to existing methods, while also delivering significant cost and environmental benefits for healthcare providers that handle large volumes of conventional blood samples.
Synartro is a Swedish research and development company that develops improved treatments using patented delivery technology combined with existing proven drugs. The preclinical lead program, SYN321, is based on a novel therapy combining diclofenac covalently bound to hyaluronan for the treatment of osteoarthritis (OA), a disease that today leaves up to 50% of patients without adequate pain relief. The company’s initial focus is in knee OA with the potential of further expansion.
SAGA Diagnostics AB is a Swedish company specializing in molecular genetic testing and services aimed at healthcare and biopharmaceutical sectors, as well as academic institutions. Founded in 2016 and based in Lund, SAGA focuses on personalized cancer genomics and disease monitoring. The company provides cutting-edge services such as cancer medicine, gene mutation analysis, and both tissue and non-invasive liquid biopsies, including blood samples. SAGA's proprietary technology enables the ultrasensitive quantification of circulating tumor DNA, achieving a detection limit of 0.001%. This advanced capability allows for the accurate detection of actionable mutations, patient stratification, and monitoring of treatment responses, thereby enhancing the management of cancer therapies and providing patients with greater peace of mind.
Capitainer AB, based in Stockholm, Sweden, specializes in the manufacture of a volumetric blood collection device designed for micro sampling with a predefined blood volume. Founded in 2016, the company provides patients with the ability to collect their own dried blood spots at home, ensuring convenience and safety. This innovative technology offers a more accurate solution compared to existing methods, while also delivering significant cost and environmental benefits for healthcare providers that handle large volumes of conventional blood samples.
Synartro is a Swedish research and development company that develops improved treatments using patented delivery technology combined with existing proven drugs. The preclinical lead program, SYN321, is based on a novel therapy combining diclofenac covalently bound to hyaluronan for the treatment of osteoarthritis (OA), a disease that today leaves up to 50% of patients without adequate pain relief. The company’s initial focus is in knee OA with the potential of further expansion.
PharmNovo AB is a Swedish biopharmaceutical company based in Lund, established in 2008. It specializes in the development of therapeutic drugs aimed at treating neuro diseases, particularly hyper excitability disorders such as chronic pain. The company's leading product, PN6047, is designed to alleviate chronic pain and address issues of hypersensitivity. PharmNovo employs a research approach that integrates advanced chemistry and bioscience to create safe, effective, and non-addictive opioid alternatives for managing nervous system disorders. By focusing on neuroscience and translational medicine, PharmNovo aims to enhance the quality of life for individuals suffering from chronic pain.
Synartro is a Swedish research and development company that develops improved treatments using patented delivery technology combined with existing proven drugs. The preclinical lead program, SYN321, is based on a novel therapy combining diclofenac covalently bound to hyaluronan for the treatment of osteoarthritis (OA), a disease that today leaves up to 50% of patients without adequate pain relief. The company’s initial focus is in knee OA with the potential of further expansion.
Empe Diagnostics is focused on addressing drug resistance in tuberculosis (TB) and sexually transmitted diseases (STDs) by creating simple and rapid diagnostic solutions for infectious diseases. The company develops diagnostic kits that offer combinatorial and confirmatory point-of-care diagnostics, particularly targeting TB and STDs. These kits enable patients to access early-stage confirmatory diagnostics, facilitating timely and effective treatment. Empe Diagnostics emphasizes the importance of combating antimicrobial resistance, positioning itself as a key player in improving diagnostic capabilities for critical health challenges.
Cavis Technologies is a start-up focused on developing healthcare devices aimed at diagnosing cardiovascular diseases. The company provides a unique device designed for invasive cardiology care units, enhancing control and safety during medical procedures. Its innovative device features a simple and robust design, utilizing a strategically positioned pressure sensor that minimizes hydrostatic error. This technology allows for effective assessment of the severity of narrowings in coronary arteries and myocardial disease, ultimately benefiting patients, cardiologists, and healthcare providers by improving diagnostic accuracy and patient outcomes.
Elypta AB is a molecular diagnostic company based in Stockholm, Sweden, focused on developing a metabolism-based liquid biopsy platform for the early detection and monitoring of cancer. Founded in 2017, Elypta's platform utilizes a new in vitro diagnostic laboratory assay kit to measure biomarkers in blood and urine, employing artificial intelligence algorithms to analyze data for cancer signatures. The company is actively involved in the clinical trial series AURORAX, which investigates the application of its technology in renal cell carcinoma, addressing aspects such as recurrence surveillance and treatment response monitoring. Elypta is exploring its platform's potential across various cancer indications, aiming to enhance early-stage cancer detection and improve patient outcomes.
Predicare AB is a company based in Gothenburg, Sweden, that specializes in designing and developing decision support system solutions for the healthcare sector. Its primary product, the RETTS system, enhances emergency triage and treatment by measuring vital parameters during initial examinations and collecting structured medical histories related to patients' symptoms and reasons for seeking care. Founded in 2010, Predicare focuses on providing efficient support for patients, families, medical staff, and healthcare providers to improve decision-making processes in medical settings.
Predicare AB is a company based in Gothenburg, Sweden, that specializes in designing and developing decision support system solutions for the healthcare sector. Its primary product, the RETTS system, enhances emergency triage and treatment by measuring vital parameters during initial examinations and collecting structured medical histories related to patients' symptoms and reasons for seeking care. Founded in 2010, Predicare focuses on providing efficient support for patients, families, medical staff, and healthcare providers to improve decision-making processes in medical settings.
Empe Diagnostics is focused on addressing drug resistance in tuberculosis (TB) and sexually transmitted diseases (STDs) by creating simple and rapid diagnostic solutions for infectious diseases. The company develops diagnostic kits that offer combinatorial and confirmatory point-of-care diagnostics, particularly targeting TB and STDs. These kits enable patients to access early-stage confirmatory diagnostics, facilitating timely and effective treatment. Empe Diagnostics emphasizes the importance of combating antimicrobial resistance, positioning itself as a key player in improving diagnostic capabilities for critical health challenges.
Empe Diagnostics is focused on addressing drug resistance in tuberculosis (TB) and sexually transmitted diseases (STDs) by creating simple and rapid diagnostic solutions for infectious diseases. The company develops diagnostic kits that offer combinatorial and confirmatory point-of-care diagnostics, particularly targeting TB and STDs. These kits enable patients to access early-stage confirmatory diagnostics, facilitating timely and effective treatment. Empe Diagnostics emphasizes the importance of combating antimicrobial resistance, positioning itself as a key player in improving diagnostic capabilities for critical health challenges.
SINGLE TECHNOLOGIES AB develops single molecule sensitive 3D imaging system for research, drug discovery, and diagnostics. The product can be used to digitize the samples. SINGLE TECHNOLOGIES AB was founded in 2012 and is based in Stockholm, Sweden.
Athera Biotechnologies AB is a biopharmaceutical company based in Stockholm, Sweden, dedicated to developing targeted anti-inflammatory therapies and companion diagnostics for cardiovascular diseases (CVD). Founded in 2002, the company focuses on identifying immunological markers associated with atherosclerosis to enhance prevention and treatment strategies for CVD. Its product portfolio includes CVDefine, an immunological marker and ELISA kit designed for cardiovascular risk assessment, as well as innovative biopharmaceuticals like Annexin A5, which aims to prevent plaque rupture, and PC-mAb, a monoclonal antibody therapy targeting the uptake of oxidized LDL in macrophages. Athera's development efforts are grounded in research from the Karolinska Institutet and aim to meet the significant unmet medical needs in anti-inflammatory therapeutics for vascular diseases.
Athera Biotechnologies AB is a biopharmaceutical company based in Stockholm, Sweden, dedicated to developing targeted anti-inflammatory therapies and companion diagnostics for cardiovascular diseases (CVD). Founded in 2002, the company focuses on identifying immunological markers associated with atherosclerosis to enhance prevention and treatment strategies for CVD. Its product portfolio includes CVDefine, an immunological marker and ELISA kit designed for cardiovascular risk assessment, as well as innovative biopharmaceuticals like Annexin A5, which aims to prevent plaque rupture, and PC-mAb, a monoclonal antibody therapy targeting the uptake of oxidized LDL in macrophages. Athera's development efforts are grounded in research from the Karolinska Institutet and aim to meet the significant unmet medical needs in anti-inflammatory therapeutics for vascular diseases.
Likvor AB is a medical device company based in Umeå, Sweden, specializing in systems for neurological investigations. Founded in 2007, the company has developed the CELDA System, which assesses cerebrospinal fluid (CSF) dynamics, essential for diagnosing conditions such as Normal Pressure Hydrocephalus (NPH). The CELDA System, which includes an instrument, software, tool set, and a specialized examination bed, was CE-marked and made available to the market in 2009. This innovative system is based on nearly 40 years of research conducted at Umeå University and Umeå University Hospital. Likvor AB is certified according to ISO-13485 and is committed to advancing methods and devices related to CSF dynamics in collaboration with academic researchers. The CELDA System is available in multiple languages, enhancing its accessibility for healthcare providers.
Lipigon Pharmaceuticals AB is a Swedish company established in 2010, specializing in the development of therapeutics for dyslipidemia and metabolic diseases. The company focuses on treatments targeting lipoprotein lipase (LPL), an enzyme linked to fat metabolism, which is crucial for individuals with conditions such as lipodystrophy, homozygous familial hypercholesterolemia, insulin resistance, and metabolic syndrome. Lipigon is particularly dedicated to orphan drug development, addressing rare diseases that lack sufficient treatment options. The company has formed a collaboration with AstraZeneca to advance LPL-targeted pharmaceuticals, with potential milestone payments totaling up to $110 million based on development and sales achievements.
Cartana AB operates as a biotechnology company which maps gene expression in brain tissue via In Situ Sequencing. The company’s products include NeuroKit: Brain Cell Mapping which identifies more than 100 genes in a single tissue section and sequencing services which perform sample preparation at laboratory and send the samples to CARTANA. Cartana AB was founded in 2017 and is headquartered in Solna, Sweden. As of August 21, 2020, Cartana AB operates as a subsidiary of 10x Genomics, Inc.
Empe Diagnostics is focused on addressing drug resistance in tuberculosis (TB) and sexually transmitted diseases (STDs) by creating simple and rapid diagnostic solutions for infectious diseases. The company develops diagnostic kits that offer combinatorial and confirmatory point-of-care diagnostics, particularly targeting TB and STDs. These kits enable patients to access early-stage confirmatory diagnostics, facilitating timely and effective treatment. Empe Diagnostics emphasizes the importance of combating antimicrobial resistance, positioning itself as a key player in improving diagnostic capabilities for critical health challenges.
Empe Diagnostics is focused on addressing drug resistance in tuberculosis (TB) and sexually transmitted diseases (STDs) by creating simple and rapid diagnostic solutions for infectious diseases. The company develops diagnostic kits that offer combinatorial and confirmatory point-of-care diagnostics, particularly targeting TB and STDs. These kits enable patients to access early-stage confirmatory diagnostics, facilitating timely and effective treatment. Empe Diagnostics emphasizes the importance of combating antimicrobial resistance, positioning itself as a key player in improving diagnostic capabilities for critical health challenges.
PictureMyLife is an innovative platform designed to enhance communication for children with impaired comprehension skills, as well as their families and educators. Founded by Yvonne Malmström Grimme, Lollo Andström, Lisa Lidgren, and Maria Skantz, the company aims to replace traditional, cumbersome methods of communication, such as handwritten contact books and printed schedules, with a more efficient digital solution. The platform allows users to upload images and videos, providing a secure way to share personal stories and experiences. With a strong emphasis on protecting user data, PictureMyLife offers a web-based communication tool that is both accessible and inspiring, ultimately making life easier for children facing communication challenges. The founders bring extensive experience in communication and education, particularly within healthcare and social care sectors, to support their mission.
Medpro Clinic Group is a healthcare provider based in Sweden, operating six care centers in the Västra Götaland region. The organization specializes in a range of services, including primary care, rehabilitation, vaccinations, dermatology, cardiology, and drug rehabilitation. By offering diverse healthcare options under one roof, Medpro Clinic Group enhances accessibility and continuity of care for its patients. The dedicated staff at Medpro Clinic Group is committed to delivering high-quality healthcare with a personal touch, ensuring that patient needs are met with integrity and professionalism.
Medpro Clinic Group is a healthcare provider based in Sweden, operating six care centers in the Västra Götaland region. The organization specializes in a range of services, including primary care, rehabilitation, vaccinations, dermatology, cardiology, and drug rehabilitation. By offering diverse healthcare options under one roof, Medpro Clinic Group enhances accessibility and continuity of care for its patients. The dedicated staff at Medpro Clinic Group is committed to delivering high-quality healthcare with a personal touch, ensuring that patient needs are met with integrity and professionalism.
Liv Diagnostics AB is a Swedish company, established in 2016 and based in Mölndal, that focuses on developing innovative diagnostic tools for cancer treatment. The company specializes in a unique product called CellRACE, which analyzes the migration capacity of tumor cells to provide predictive insights regarding the risk of metastasis. This technology adopts a direct analysis approach, allowing for the observation of cancer cell behavior in a simulated natural environment, which is a departure from traditional indirect diagnostic methods. By quantifying the migration behavior of living cells, Liv Diagnostics aims to enhance the ability of physicians to assess cancer progression and make informed treatment decisions. The company operates as a subsidiary of Cline Scientific AB.
Raytelligence AB is a Swedish company based in Halmstad that specializes in microwave sensors for the healthcare and industrial markets. It offers a notable product, RayVS1, which is a radar sensor designed for monitoring vital signs such as heartbeat, movement, and body position in humans and animals. Raytelligence has developed solutions aimed at elderly care, allowing for effective home monitoring. The company emerged in 2015 as a subsidiary of Swedish Adrenaline, which serves as a holding company for developing electronic products in the health and sports sectors. Raytelligence has received grants for innovation and has made significant advancements, including the certification of its RayVS1 sensor for home use in 2017. The company has also established partnerships with major IT providers in the e-Health market and has expanded its reach to the road construction sector, demonstrating versatility in its applications. The team at Raytelligence comprises professionals skilled in industrial design and radar signal processing.
1928 Diagnostics is a digital health company, crunching DNA data in the cloud, to enable healthcare providers fight antibiotic resistance. Our software service provide revolutionary outbreak tracing and diagnostics for full infection control at any hospital.
MedFilm specializes in enhancing communication within the healthcare sector by providing 3D animated films that convey information about surgical interventions to patients. The company's platform offers these animated films in over a dozen languages, aiming to improve patient understanding, confidence, and participation in their healthcare journey. These films are utilized in hospitals across Scandinavia, presented on waiting room screens and through film tablets that offer information upon patient admission and awakening. By making complex medical information accessible and engaging, MedFilm supports healthcare providers in delivering effective patient education and care.
PictureMyLife is an innovative platform designed to enhance communication for children with impaired comprehension skills, as well as their families and educators. Founded by Yvonne Malmström Grimme, Lollo Andström, Lisa Lidgren, and Maria Skantz, the company aims to replace traditional, cumbersome methods of communication, such as handwritten contact books and printed schedules, with a more efficient digital solution. The platform allows users to upload images and videos, providing a secure way to share personal stories and experiences. With a strong emphasis on protecting user data, PictureMyLife offers a web-based communication tool that is both accessible and inspiring, ultimately making life easier for children facing communication challenges. The founders bring extensive experience in communication and education, particularly within healthcare and social care sectors, to support their mission.
Inhalation Sciences specializes in developing and commercializing advanced laboratory instruments for inhalation research. The company's flagship product, PreciseInhale, is a patented aerosol generation platform that facilitates the delivery of respirable dry powder aerosols, supporting drug development from preclinical studies to human clinical trials. This innovative system operates on a one-animal-at-a-time basis, requiring only milligrams of test substances, which significantly reduces costs and accelerates timelines for pharmacokinetic studies. Additionally, PreciseInhale provides high-resolution lung data with typically less than 10% standard deviation. Inhalation Sciences also offers the LaminarPace tool, designed for drying small amounts of drug substances. The company conducts contract research for both novel and generic inhalation drug developers, as well as for toxicology and environmental research institutes and academic institutions in the field of inhalation and aerosolization.
Inhalation Sciences specializes in developing and commercializing advanced laboratory instruments for inhalation research. The company's flagship product, PreciseInhale, is a patented aerosol generation platform that facilitates the delivery of respirable dry powder aerosols, supporting drug development from preclinical studies to human clinical trials. This innovative system operates on a one-animal-at-a-time basis, requiring only milligrams of test substances, which significantly reduces costs and accelerates timelines for pharmacokinetic studies. Additionally, PreciseInhale provides high-resolution lung data with typically less than 10% standard deviation. Inhalation Sciences also offers the LaminarPace tool, designed for drying small amounts of drug substances. The company conducts contract research for both novel and generic inhalation drug developers, as well as for toxicology and environmental research institutes and academic institutions in the field of inhalation and aerosolization.
Inhalation Sciences specializes in developing and commercializing advanced laboratory instruments for inhalation research. The company's flagship product, PreciseInhale, is a patented aerosol generation platform that facilitates the delivery of respirable dry powder aerosols, supporting drug development from preclinical studies to human clinical trials. This innovative system operates on a one-animal-at-a-time basis, requiring only milligrams of test substances, which significantly reduces costs and accelerates timelines for pharmacokinetic studies. Additionally, PreciseInhale provides high-resolution lung data with typically less than 10% standard deviation. Inhalation Sciences also offers the LaminarPace tool, designed for drying small amounts of drug substances. The company conducts contract research for both novel and generic inhalation drug developers, as well as for toxicology and environmental research institutes and academic institutions in the field of inhalation and aerosolization.
Learning to Sleep AB is a digital care provider based in Malmo, Sweden, specializing in evidence-based improvement programs for individuals experiencing sleep disorders. Founded in 2010, the company offers two primary products: "Improve my Sleep," aimed at those with minor sleep issues requiring slight adjustments, and "Learning to Sleep," designed for individuals with more severe conditions to help restore their sleep memory. These clinically proven programs are accessible through web and mobile platforms, allowing users to engage with the treatment conveniently. Learning to Sleep has successfully assisted over 40,000 individuals, fostering a strong connection between patients and their psychologists through its unique business model.
Learning to Sleep AB is a digital care provider based in Malmo, Sweden, specializing in evidence-based improvement programs for individuals experiencing sleep disorders. Founded in 2010, the company offers two primary products: "Improve my Sleep," aimed at those with minor sleep issues requiring slight adjustments, and "Learning to Sleep," designed for individuals with more severe conditions to help restore their sleep memory. These clinically proven programs are accessible through web and mobile platforms, allowing users to engage with the treatment conveniently. Learning to Sleep has successfully assisted over 40,000 individuals, fostering a strong connection between patients and their psychologists through its unique business model.
Attana AB, founded in 2002 and headquartered in Stockholm, Sweden, specializes in providing biologically relevant information to enhance the efficiency of pharmaceutical drug development, primarily in Europe and Asia. The company develops third-generation analytical biosensor instruments that facilitate automated analysis of molecular interactions with various biological entities, including cells, antibodies, proteins, viruses, and bacteria. These biosensors are utilized to assess binding characteristics such as specificity, kinetics, and affinity. Attana also offers contract research services, catering to a diverse clientele that includes academic institutions, biotechnology firms, and pharmaceutical companies. Their technology has received validation from various stakeholders in the scientific and pharmaceutical communities worldwide.